Research and development sponsored by the
biomedical/pharmaceutical industry plays an important role in biomedical
research, and significant scientific discoveries have been made through
collaboration between the biomedical/pharmaceutical industry and non-industry
researchers. We are partners with complementary roles in the quest for
the prevention and cure of blood diseases.
ASH is committed to fostering the dissemination
of evidence-based, peer-reviewed science. While industry endorses this mission,
its business strategy requires the marketing of products to physicians.
These two objectives create the need for clear guidelines that ensure the
separation of ASH’s educational functions from industry’s product-marketing
A set of principles will be the basis for
formulating rules and guiding decision-making where industry is involved.
For ASH meetings:
- ASH is committed to the presentation of an objective
educational and scientific program, as well as to the presentation of
peer-reviewed scientific abstracts; as a result of that commitment, ASH should
be the sole provider of all educational and scientific programming during ASH’s
official meetings. For meetings scheduled to last more than one day, ASH
will be the only provider of education between the start of the event and the
end of the event, even if the program lasts several days.
- As an accredited Continuing Medical Education (CME) provider, the Society is committed to
complying with the requirements set forth by the Accreditation Council for Continuing Medical Education (ACCME).
- ASH values the relationships it has with pharmaceutical and
biomedical companies and recognizes that ASH meetings provide a natural forum
for meeting attendees to interact with representatives of the pharmaceutical
- ASH recognizes that the ASH annual meeting is an
opportunity for companies to convene meetings of their current investigators to
provide updates on research.
- ASH recognizes that most pharmaceutical companies are
committed to complying with the PhRMA code and is supportive of this effort
even as the implications of this voluntary guideline are being evaluated on a
- The broad scope of ASH’s meetings often makes it
challenging for meeting participants to attend all the ASH-sponsored sessions
they wish to attend; for this reason, pharmaceutical and biomedical companies
are required to avoid sponsoring any events that might conflict with the formal
ASH educational/scientific program.
- ASH recognizes the importance of the Friday Satellite
Symposia to our members and to pharmaceutical and biomedical companies, device
manufacturers, and nonprofit organizations. These meetings, which fall
outside of the scope of the official ASH annual meeting, provide a forum for
companies to provide CME-accredited education for physicians that supplements
the educational experience of meeting attendees. They should not be used as a
forum to focus on business interests.
is committed to holding high-quality meetings and strongly discourages any
behavior that could diminish the professional nature of our meetings: in the exhibit
hall, during the Friday Satellite Symposia, or in conjunction with the
ancillary meetings or during educational sessions. ASH has adopted principles
to underscore its commitment to avoid bias, as well as policies that lay out
specific ways in which the Society safeguards the integrity of the programs and
activities in which its membership is engaged. We expect our corporate
partners to embrace both the letter and spirit of these principles when
participating in ASH meetings and respect the safeguards that have been
back to top